Rocket Pharmaceuticals to Present at Upcoming Investor Conferences

NEW YORK--()--Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will present a company overview at the following investor conferences:

  • Bank of America Merrill Lynch Health Care Conference 2018 on May 15, 2018, at 9:20 a.m. Pacific Time in Las Vegas, NV.
  • UBS Global Healthcare Conference on May 23, 2018, at 9:30 a.m. Eastern Time in New York City.

A live audio webcast of the UBS presentation will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for an undisclosed rare pediatric disease. For more information about Rocket, please visit www.rocketpharma.com.

Contacts

Rocket Pharmaceuticals, Inc.
Claudine Prowse, Ph.D.
SVP Corporate Development and IRO
The Alexandria Center for Life Science
430 East 29 Street, Suite 1040
New York, NY 10016
cp@rocketpharma.com

Recent Stories

RSS feed for Rocket Pharmaceuticals, Inc.

Release Summary

Rocket Pharmaceuticals to Present at Upcoming Investor Conferences

Rocket Pharmaceuticals, Inc.